SynthesisJournal of oral & facial pain and headache2026
Slow-inactivated sodium channels as a therapeutic target in trigeminal neuralgia: evidence from a systematic review and meta-analysis of lacosamide.
Synthesis in Journal of oral & facial pain and headache, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chasing the Wrong Door for 30 Years: Is Suzetrigine the Key to Selective Pain Relief?Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLacosamide (LCM), a selective enhancer of the slow inactivation of voltage-gated sodium channels, has been proposed as a treatment for trigeminal neuralgia (TN), although its clinical efficacy and safety remain incompletely defined.
methodsWe conducted a systematic review and meta-analysis of cohort studies involving adults with TN. PubMed, EMBASE, and CENTRAL were searched from inception to 16 October 2025. The primary outcomes were efficacy, measured as pain relief, and safety, assessed by adverse events (AEs) associated with LCM.
resultsFour studies were included in the quantitative synthesis. The pooled proportion of patients achieving pain relief with oral LCM was 66.7% (95% confidence interval (CI): 57.3%-74.9%;
conclusionLacosamide (LCM) has shown favorable outcomes in some patients with trigeminal neuralgia (TN) and may serve as an alternative therapy, particularly those refractory to or intolerant of first-line agents, and intravenous LCM may be useful for acute exacerbations. However, the current evidence is preliminary, observational, and insufficient to support comparative treatment decisions. Randomized controlled trials are needed to establish its efficacy and safety. THE PROSPERO REGISTRATION: CRD420261295578.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.